DYADIC INTERNATIONAL INC: Nasdaq Listing Update

This report breaks down the latest news regarding Dyadic International Inc. in plain English so you can understand what’s happening with your investment without needing a finance degree.

1. What happened?

Dyadic International, a biotech firm known for its C1-cell protein production platform, received a formal warning from Nasdaq. The company’s stock traded below the $1.00 minimum price for 30 consecutive business days. Additionally, the company fell below the requirement of maintaining at least $2.5 million in stockholders' equity.

2. When did it happen?

Dyadic received this official notification from Nasdaq on June 18, 2026.

3. Why does this matter?

This is a significant red flag. If Nasdaq removes the stock, it moves to "over-the-counter" (OTC) markets. OTC trading often has lower liquidity and wider price gaps, making it harder and more expensive to trade. Furthermore, delisting can sometimes trigger loan defaults and limit the company’s ability to raise new capital from traditional institutional investors.

4. Who is affected?

• Investors: Shareholders face uncertainty. If the stock moves to OTC markets, many institutional investors are forced to sell their shares because their internal rules forbid holding non-listed stocks, which can put downward pressure on the price.
• The Company: Management must now dedicate significant time and resources to the Nasdaq hearing process. This can be a distraction from their core business of licensing their C1 gene expression platform and developing biopharmaceutical products.

5. What happens next?

Dyadic has requested a hearing before a Nasdaq panel to appeal the delisting.

• The "Stay": This request automatically pauses any immediate delisting until the panel makes a final decision.
• The Goal: The company is working to present a plan to regain compliance. They are aiming to meet the minimum price and equity requirements by December 15, 2026.

6. What should you watch for?

• Expect Volatility: The stock price will likely swing as the market reacts to the uncertainty of the hearing process.
• The Hearing Outcome: This is the most important upcoming event. If the panel grants an extension, the company gets more time to recover. If they deny the request, delisting will follow shortly after.
• Monitor Financials: Keep a close eye on the company’s cash burn and revenue from C1 licensing deals. To return to compliance, the company needs either a significant increase in revenue or a successful capital raise to push their equity back above the $2.5 million threshold.

Final Thought for Investors: This is a "wait-and-see" situation. While the hearing provides a temporary safety net, the core issue remains the company's financial health. Before making any moves, look for official updates regarding the hearing date and any announcements about new licensing deals or funding, as these will be the primary drivers of whether the company can stay on the Nasdaq.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered financial advice. Always do your own research or consult with a professional before making investment decisions.